Xtl Biopharmaceuticals Ltd - Initial Statement of Beneficial Ownership (3)
September 04 2008 - 12:11PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Expires:
February 28, 2011
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
WEINER BEN-ZION
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
8/27/2008
|
3. Issuer Name
and
Ticker or Trading Symbol
XTL BIOPHARMACEUTICALS LTD [XTLB]
|
(Last)
(First)
(Middle)
C/O XTL BIOPHARMACEUTICALS LTD,, 711 EXECUTIVE BLVD., SUITE Q
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Street)
VALLEY COTTAGE, NY 10989
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
OPTIONS TO PURCHASE ORDINARY SHARES
|
2000000
(1)
|
D
|
|
ORDINARY SHARES
|
50000
(2)
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
(
1)
|
Options to purchase ordinary shares which vest upon achievement of certain market capitalization based milestones (1/3 upon
the achievement of $150 million market capitalization, 1/3 upon the achievement of $250 million market capitalization, and
1/3 upon the achievement of $350 million market capitalization, in each case as set out in the option agreement under which
Dr. Weiner was granted the options). As of the filing date, 666,667 options have vested.
|
(
2)
|
On August 27, 2008, Mr. Weiner purchased 50,000 ordinary shares at an average price of NIS 1.546 (equivalent to $0.433USD)
per share on the Tel Aviv Stock Exchange.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
WEINER BEN-ZION
C/O XTL BIOPHARMACEUTICALS LTD,
711 EXECUTIVE BLVD., SUITE Q
VALLEY COTTAGE, NY 10989
|
X
|
|
|
|
Signatures
|
/s/ Ben-Zion Weiner
|
|
8/29/2008
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Sep 2024 to Oct 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Oct 2023 to Oct 2024